Crossmark

Impact of neoadjuvant imatinib duration and tumor response on recurrence-free survival in locally advanced gastrointestinal stromal tumors: a retrospective multicenter cohort study

Crossref DOI link: https://doi.org/10.1186/s12957-026-04291-w

Published Online: 2026-03-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Zong, Haoyu

Kou, Youwei

Song, He

Lan, Zhongmin

Mu, Yongrun

Xiao, Qifeng

Jin, Xin

Li, Yunlong

Xiang, Shuai

Huo, Yiyao

Zhou, Mengjie

Zhang, Xiaoyan

Wu, Xin

Zhang, Jianwei
Funding

Funding for this research was provided by:

National High Level Hospital Clinical Research Funding and National Cancer Center Climbing Fund (No. NCC202404004)
License Information

Text and Data Mining valid from 2026-03-10

Version of Record valid from 2026-04-17
More Information

Article History

Received: 6 December 2025

Accepted: 4 March 2026

First Online: 10 March 2026

Declarations

:

: This study adhered to the Helsinki Declaration and received approval from the IRB of the national cancer center (S2024-332-02). All data were collected and analyzed in compliance with local data protection regulations, and patient information was fully anonymized. Informed consent was waived by the IRB because the study was observational and noninvasive.

: All the authors have read the manuscript, approved its contents and its publication. The manuscript has not been published or submitted for publication elsewhere.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below